SRZN - NASDAQ
Surrozen, Inc.
$24.52
+0.90%Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotSurrozen, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Surrozen, Inc. Income Statement
SRZN • NASDAQ
| Surrozen, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
3.5M | 10.7M | 0.0 | 12.5M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(537K) | (0.0) | (27.2M) | (3.3M) | (3.3M) | (2.9M) | (0.0) | |
2.9M | 10.7M | -27.2M | 9.2M | -3.3M | -2.9M | 0.0 | |
OPERATING INCOME | |||||||
(45M) | (36.2M) | (18.6M) | (53.6M) | (51.1M) | (29.9M) | (24.8M) | |
(16.2M) | (15.1M) | (15.8M) | (19.8M) | (14.2M) | (7.1M) | (5.5M) | |
(29.4M) | (21.1M) | (27.2M) | (37M) | (36.9M) | (25.7M) | (19.6M) | |
-42.1M | -25.5M | -45.8M | -44.3M | -54.4M | -32.8M | -25.1M | |
PRE-TAX INCOME | |||||||
3M | 1.7M | 2.3M | 781K | 72K | 91K | 0.0 | |
-537K | (0.0) | -24.5M | -3.3M | (0.0) | -2.9M | -300K | |
-199.9M | -38M | 2.7M | 8.3M | -257K | 91K | 744K | |
-242M | -63.6M | -43M | -36M | -54.6M | -32.7M | -24.4M | |
NET INCOME | |||||||
-242M | -63.6M | -43M | -36M | -52.5M | -32.6M | -24.4M |
SEC Filings
SRZN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
S-3 S-3 N/A | March 23, 2026 | March 23, 2026 | ||
8-K 8-K 2026 N/A | January 30, 2026 | January 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 07, 2025 | 2025 |
Related Guides
Continue your SRZN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.